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Heteroduplex tracking assays (HTAs) of Plasmodium falciparum merozoite surface protein 1 block-2 were
used to assess complexity of infection and treatment efficacy in a trial of three antimalarial treatments in 141
Malawian pregnant women. An elevated complexity of infection (COI) was associated with anemia, parasite
burden, and human immunodeficiency virus infection but was not associated with age or gravidity. Compar-
isons of HTA patterns before and after treatment allowed the classification of 20 of 30 (66%) recurrent episodes
as either definite treatment failures or reinfections. An elevated COI was strongly associated with treatment
failure (P  0.003). An algorithm was developed to assign a probability of failure for the 10 indeterminate
participants, some of whose infections shared a single variant of high prevalence (>10%). By summing these
probabilities, treatment efficacy was estimated.
More than 500 million people suffer from Plasmodium fal-
ciparum malaria each year. The majority of all malaria infec-
tions occur in sub-Saharan Africa, where there is often intense
year-round exposure to infected mosquitoes (20). Probably as
a result of frequent infectious bites, malaria infections in sub-
Saharan Africa are usually polyclonal (2, 3, 13). Individual
patients have been infected with as many as 14 genetically
distinct parasite subpopulations or “variants” (3, 6, 11). The
complexity of infection (COI), which is the number of variants
in an individual host, has been measured by a variety of mo-
lecular methods. These methods include nested PCR, restric-
tion fragment length polymorphism, microsatellite analysis, py-
rosequencing, and PCR with a fluorescence primer followed by
capillary electrophoresis (7, 14, 19, 21).
Using these molecular tools, a higher COI has been associ-
ated with symptomatic malaria manifestation in pregnant
women (3). In a recent study, the risk of treatment failure in
children was positively correlated with the COI (13).
The current World Health Organization protocol recom-
mends that all clinical efficacy studies with more than 14 days
of follow-up use PCR-based methods to determine whether
recurrent infection is due to drug failure (recrudescence) or a
newly acquired infection (reinfection) (25). The inherent lim-
itations of conventional nested PCR genotyping, such as sen-
sitivity only to size differences, and different interpretations of
the PCR comparisons can both have a dramatic impact on the
treatment failure rate (18). Therefore, more definitive meth-
ods are needed.
We have previously used the heteroduplex tracking assay
(HTA) in an area of low malaria transmission to characterize
the COI in Southeast Asia (15, 26). In the HTA, radiolabeled
P. falciparum merozoite surface protein 1 (PfMSP1) probe is
annealed to amplicons from a patient whose PfMSP1 block-2
region has undergone a single round of PCR amplification.
Double-stranded complexes are formed between the probe
and host amplicon(s); these complexes, termed heterodu-
plexes, migrate on a nondenaturing gel at various speeds based
on the complementarity of the patient-probe complexes. Clus-
tered base-pair mismatches, insertions, and deletions all
change the migration speed of the heteroduplexes and, after
electrophoresis on a nondenaturing gel, the host PfMSP1 se-
quence variants can be quantified. Because they are simple to
perform, sensitive to size and clustered sequence polymor-
phisms, and allow quantification of each sequence variant,
HTAs are commonly used by virologists to characterize poly-
clonal human immunodeficiency virus (HIV) infections (5, 10).
We report here the first use of the HTA to characterize P.
falciparum sequence diversity in an area of high malaria trans-
mission and discuss a new approach to determine the rate of
treatment failure.
(These results were presented in part at the 54th Annual
American Society for Tropical Medicine and Hygiene Confer-
ence, Washington, DC, 2005 [abstr. 1007].)
MATERIALS AND METHODS
Patient samples and information. A full description of the study describing the
samples used in this report is in preparation (L. Kalilani et al., unpublished data).
Briefly, 141 pregnant women with slide-confirmed P. falciparum infections and
estimated gestational ages of 14 to 26 weeks were recruited into a randomized,
open-label study conducted at the Mpemba and Madziabango Health Centers in
Blantyre District, Malawi. Women were excluded from the study if they met any
of the following conditions: multiple gestation; history of tuberculosis or diabe-
tes; mental disorder; known allergies to sulfonamides, macrolides, or py-
rimethamine; and pregnancy complications at enrollment or if they had taken
antimalarial drugs 28 days prior to enrollment. Women received directly ob-
served treatments with either standard doses of sulfadoxine-pyrimethamine (SP;
1,500 mg of sulfadoxine and 75 mg of pyrimethamine), SP plus azithromycin (1
g/day for 2 days), or SP plus artesunate (200 mg/day for 3 days). Women returned
to the clinic at least 28 days later for routine antenatal care, which included
obtaining the body temperature, a malaria smear, and a second dose of the study
treatment. After each treatment, thick smears were prepared on days 1, 2, 3, 7,
and 14. Women with fever who returned for unscheduled visits were tested for
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malaria; women with parasites between days 7 and 28 posttreatment were given
quinine (600 mg, three times/day, for 5 days).
Malaria was diagnosed by microscopic inspection of Giemsa-stained thick
blood films. The total number of parasites detected per 200 leukocytes was
multiplied by 30 to estimate the parasite count per microliter of blood (assuming
a leukocyte count of 6,000 leukocytes/ml of blood). A thick film was considered
negative if no parasites were detected after examining 100 microscopic fields.
Parasite density was dichotomized at the median value (930 parasites/l) into
categories of high and low parasite density.
Women were offered counseling and testing for HIV and nevirapine according
to the HIVNET-012 protocol if they were HIV positive. HIV testing was per-
formed by using the Determine HIV-1/2 rapid test (Abbott Laboratories) and
Unigold Test (Trinity Biotech, Dublin, Ireland). Discordant results were re-
solved with the Hemastrip Rapid Test (Saliva Diagnostic Systems).
The hemoglobin concentration was measured by using a HemoCue machine
(HemoCue, Inc., Angelholm, Sweden). Women were considered anemic if their
hemoglobin concentration was 11 g/dl.
DNA isolation. Venous blood was spotted onto filter paper and stored under
desiccation. DNA was extracted from the filter paper by using the QIAMP DNA
minikit (QIAGEN, Valencia, CA) according to the manufacturer’s instructions.
PCR. Block-2 of PfMSP1 (22) was amplified with a Peltier thermal cycler (MJ
Research, Waltham, MA) according to the protocol of Ngrenngarmlert et al.
(15) using the primers C1F (5-GAAGATGCAGTATTGACAGG-3) and C3R
(5-TGATTGGTTAAATCAAAGAG-3) (8); the C1F primer starts at nucleo-
tide 106 in the 3D7 MSP1 gene (9). PCR products were run on a 1% agarose gel,
stained with ethidium bromide, visualized by UV light, and sized against a 100-bp
molecular weight marker (Promega, Madison, WI). Successful amplification
resulted in a product of approximately 400 bp. All PCRs were done in duplicate.
Plasmids and probes. The COI was determined using a single, heterologously
expressed PfMSP1 block-2 probe (MHP [described in reference 15]). Ten mi-
crograms of the MHP-pT7Blue construct was digested with BamHI at 37°C for
1 h and then end labeled in the same buffer by filling in the BamHI overhang
for15 min at 25°C (1 BamHI buffer [New England Biolabs], 10 mM dithiothre-
itol, 50 M dGTP, 50 Ci of [-35S]dATP [1,250 Ci/mmol; ICN], 10 U of Klenow
fragment). The reaction was stopped by the addition of EDTA (1 mM final
concentration) and heat inactivation at 75°C for 15 min. The radiolabeled probe
was released from the vector by digestion with PstI at 37°C for 1 h, separated on
an agarose gel, excised, and gel purified with the QIAquick gel extraction kit
(QIAGEN).
Heteroduplex tracking assay. A total of 8 l of PCR-amplified block-2 of
PfMSP1 from patient samples was mixed with 1.2 l of 10 annealing buffer (1
M NaCl, 100 mM Tris-HCl [pH 7.5], 20 mM EDTA), 0.1 M C1F primer, 0.1
M C3R primer, 1 l of 35S-labeled probe, and 2 l of 6 loading dye (15%
Ficoll, 0.25% bromophenol blue, 0.25% xylene xylanol [Sigma, St. Louis, MO])
in a total volume of 12 l. The mixture was denatured at 95°C for 2 min and
allowed to reanneal at 25°C for 5 min. Heteroduplexes were electrophoresed on
a 6% polyacrylamide gel (acrylamide-bisacrylamide, 37.5:1) in 1 Tris-borate-
EDTA buffer at 17 mA per gel for 5.5 h. The gels were dried onto filter paper
(Whatman) and exposed to BioMax MR X-ray film (Kodak, Rochester, NY).
For quantitative data, the dried gels were exposed to a phosphorimager screen
for 7 days, and the band intensities were determined by quantifying the area
under the curve according to the manufacturer’s instructions (Molecular Dy-
namics). HTA bands were considered unique PfMSP1 sequence variants if they
were not in the probe alone lane and they were present in both PCR replicates.
The relative migration distance (Rf) was calculated for each variant by dividing
the distance migrated by the variant by the distance migrated by the probe
homoduplex. To test the precision of the Rf measurement, a single variant was
run on 16 separate gels and the Rf was calculated. The cloned variant had a
coefficient of variation of 14% (the average Rf was 0.16, and the standard
deviation was 0.022).
Colony PCR. The PfMSP1 amplicon from participant 1/019 was cloned into
the pCR2.1TOPO by using the Invitrogen TOPO TA cloning kit and trans-
formed into Escherichia coli (Invitrogen Corp., Carlsbad, CA). Then, 52 colonies
were selected and PCR amplified using the primers and thermal cycler settings
described above. PCR products from representative variants were cleaned by
using the QIAquick PCR purification kit (QIAGEN) and sequenced using the
C1F primer at the University of North Carolina-Chapel Hill Genome Analysis
Facility. DNA sequences were hand cleaned, aligned with CLUSTAL X (http:
//www2.ebi.ac.uk/clustalw), and displayed with GeneDoc (http://www.psc.edu
/biomed/genedoc/).
Statistics and modeling. The association between the COI and clinical fea-
tures was tested by using the Wilcoxon rank-sum test. The relationship between
the COI and treatment failure was monotonic (data not shown), and therefore
COI was coded as a continuous variable in the multivariable regression. Primi-
gravidity and parasite burden (dichotomized at the median) were used as co-
variates in the multivariable regression. All statistical analysis was done by using
STATA v.8.2, (STATACorp, College Station, TX).
Ethical approval and consent. This study was approved by the College of
Medicine Research Committee (University of Malawi, Blantyre, Malawi) and the
Institutional Review Boards of the University of North Carolina (Chapel Hill,
NC). Separate consent forms in the local language were administered for blood
and/or data collection and for HIV testing.
GenBank accession numbers. Six MSP1 block-2 sequences from participant
1/019 are deposited in GenBank under accession numbers DQ855130 to
DQ855135. The MHP probe is deposited under accession number DQ858166.
RESULTS
Clinical characteristics. We successfully PCR amplified the
PfMSP1 block-2 in 125 of the 141 (88.7%) pregnant women
enrolled. The average parasite density of the amplified samples
was 1,815 parasites/l (median  930, range  120 to 22,500).
The parasite density of the samples that did not amplify (me-
dian  705 parasites/l) was similar to those that did amplify
(P  0.915 [Wilcoxon rank-sum test]). Of those with a positive
PCR, the average age at enrolment was 21 years (median  20,
range  15 to 39); 56% were primigravid, 72% were anemic,
and 25 of the 80 (31%) women who accepted HIV testing were
HIV infected.
FIG. 1. Representative PfMSP1 HTA. The COI is shown for four
women at enrollment (I), during their second visit (II), or during
delivery (Pe). All samples were run in duplicate, with the number of
unique PfMSP1 variants per sample listed at the bottom. ssProbe,
single-stranded probe; P, probe alone; C, AF42 plasmid control.
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PfMSP1 sequence variation. HTAs were run, in duplicate,
on the 125 patients, and the numbers of variants were deter-
mined. A representative gel is shown in Fig. 1; sequence vari-
ants migrated both above and below the single-stranded probe.
The participants had a mean COI of 3.82 (median  3, range 
1 to 11). The distance migrated by each variant was mea-
sured, and the variants were divided into 20 bins of 0.05 Rf
units. The prevalence of individual variants ranged from
0.03 to 15.75%, and three variants were present in 10% of
the women (Fig. 2).
COI and clinical features. The relationship between the
COI at enrollment (i.e., the first malaria episode) and clinical
features was investigated. A small, positive association be-
tween the COI and the log10 parasite density was observed
(correlation coefficient  0.22, P  0.0117). An increased COI
was also associated with both anemia and HIV infection (Table
1). Women who failed the first treatment had a greater COI
than those who did not fail (median  five versus three vari-
ants; P  0.0003); the COI was similar among the three study
arms (P  0.109 [Kruskal-Wallis test]). After we adjusted for
the parasite burden and primigravidity, we found that the COI
remained independently associated with anemia, HIV status,
and treatment failure (Table 1). A small association was ob-
served between the COI and reinfection (median COI  4
versus 3; P  0.106), which weakened after we adjusted for
parasite burden and primigravidity (Table 1).
Variant subpopulations within a single host. Using colony
PCR as the reference standard, we assessed the ability of the
HTA to accurately measure the proportion of each variant within
a single host. The PfMSP1 amplicon from one participant with 10
variants was TA cloned, and 52 colonies were selected. The
PfMSP1 block-2 from each of the colonies was PCR amplified
and rescreened by the HTA. The proportion of colonies contain-
ing each variant (Fig. 3A, left panel) was compared to the phos-
phorimager-derived scan of the donor population (Fig. 3A, mid-
dle and right panels). There was a strong, positive correlation
between phosphorimager intensity and the number of clones with
the corresponding variant (R2  0.93). Four HTA variants rep-
resenting 3% of total population (variants 1, 3, 4, and 9) were
not represented among the 52 colonies selected.
Next, 15 clones from the same participant were sequenced
and all were identified as PfMSP1 block-2. Figure 3B shows
the alignment of six representative MSP1 sequences; this
alignment includes a variant that migrated rapidly through
the gel, near the probe homoduplex (variant 10), four vari-
ants that migrated near the single-stranded probe (variants
5 to 8), and a variant that migrated very slowly (variant 2).
The sequenced variants ranged from 307 to 391 nucleotides,
and three of the variants were within 20 nucleotides of each
other. Besides its sensitivity to size polymorphisms, the
HTA was also sensitive to sequence polymorphisms and, as
expected, the sequences that were most divergent from the
probe migrated the farthest distance from the probe homo-
duplex (data not shown).
Classification of recurrences. One important potential use
of HTA would be to distinguish new infections (reinfections)
from treatment failures (recrudescences). Many reports use
PCR to distinguish reinfection from treatment failure but do
not specify the criteria used to distinguish each outcome. Of-
ten, if the initial and recurrent infections share any variant,
then the recurrent infection is classified as a treatment failure
(12, 17). However, in an area of high malaria transmission,
such as Malawi, if specific PfMSP1 variants are frequent in the
FIG. 2. Prevalence of PfMSP1 sequence variants at enrollment.
The line indicates the cutoff point for abundant (“common”) versus
nonabundant variants.










P b Adjusted OR(95% CI)c
Subject age (yr)
20 73 (58) 3 (2–4) 0.54
20 52 (42) 3 (2–5)
Gravidity
Primigravid 71 (57) 3 (2–5) 0.52
Multigravid 54 (43) 3 (2–5)
Parasitemiad
Low 62 (50) 3 (2–5) 0.112
High 63 (50) 3 (2–6)
Anemiae
No 35 (28) 3 (2–4) 0.052 Referent
Yes 90 (72) 3 (2–6) 1.21 (0.98–1.48)
HIV infection
Negative 55 (69) 3 (2–4) 0.035 Referent
Positive 25 (31) 3 (3–6) 1.29 (1.01–1.65)
Treatment failuref
No 104 (83) 3 (2–4) 0.0003 Referent
Yes 21 (17) 5 (4–8) 1.50 (1.08–2.08)
Reinfectionf
No 111 (89) 3 (2–5) 0.106 Referent
Yes 14 (11) 4 (3–6) 1.15 (0.87–1.53)
a IQR, interquartile range.
b As determined by the Wilcoxon rank-sum test.
c OR, odds ratio. The OR was adjusted for primigravidity and parasitemia (low
or high). CI, confidence interval.
d That is, 930 parasites/l of blood.
e That is, a hemoglobin level of 11.0 g/dl.
f Failing first drug treatment only.
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parasite population, then a new infection containing one of
these variants might be misclassified as a failure. In the present
study, three variants were common, with prevalences between
11 and 16% (Fig. 2). Since the average infection comprised
four variants, any recurrent infection had a 37 to 50% chance
of containing each of these variants coincidentally. To elimi-
nate the possibility of misclassifying patients with these com-
mon variants as failures, we consider a second episode inde-
terminate if the initial and recurrent episodes only shared one
band with a prevalence 10%.
FIG. 3. Comparison of HTA and colony PCR. The PfMSP1 amplicon from patient 1/019 was TA cloned and subjected to colony PCR. Next,
52 colonies were picked and rescreened with the MHP HTA. (A) The relative abundance of each variant after colony PCR (left panel),
autoradiography of the HTA complexes (middle panel), and the phosphorimager-quantified relative abundance of each of the 10 variants in the
parent population (right panel) are shown. Variant numbers correspond to the sequences listed in panel B. The probe homoduplex is not shown
but runs just below variant 10. (B) Pairwise alignment of six representative sequences isolated by colony PCR from patient 1/019.
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Comparison of first and second malaria episodes. Table 2
summarizes the HTA patterns of 35 women with second
malaria episodes. Five patients failed treatment within 14
days and were considered early treatment failures. Thirty
patients had a second infection 14 to 56 days posttreatment.
Six of these shared multiple and/or uncommon PfMSP1
variants with the first episode with no new variants and were
considered late treatment failures. Four shared no variants
with the first episode and were considered reinfections. The
remaining 20 women had recurrent infections that both
shared variants with the initial infection and contained new
ones. For 10 of these participants, either the shared variant
was uncommon (10% prevalence) or two common variants
were shared, and the second episode was classified as a late
treatment failure. For the remaining 10 patients, the single
shared variant was common (10% prevalence), and the
second episode was considered indeterminate.
Of the 35 women with second episodes, 11 experienced
recurrences (third episodes) (Table 2). Two failed within 14
days and were classified as early treatment failures. Nine epi-
sodes occurred 14 to 28 days posttreatment; two of these were
classified as late treatment failures, three were classified as
reinfections, and four were classified as indeterminate by the
criteria used for the second episodes.
Estimation of true failure rate. Thus, there were 10 second
episodes and 4 third episodes that were classified as indeter-
minate. Fortunately, since we know the prevalence of the com-
mon bands and the number of variants in the recurrent epi-
sode, we can calculate a probability of reinfection by each
variant. For the recurrent patient with x variants and sharing a
single variant of prevalence y, the binomial probability (16)
that this variant is found by chance in a recurrent infection is
calculated as 1 	 (1 	 y)x [and therefore the probability that it
represents a failure is (1 	 y)x]. The probabilities of reinfection
for the 14 indeterminate episodes are shown in Table 3. The
mean probabilities of failure are 0.59 for the 10 indeterminate
second episodes (or a predicted 5.93 patients) and 0.48 for the
4 indeterminate third episodes (or a predicted 1.91 patients).
Thus, the estimated failure rates are (21  5.93)/125 or 21.5%
for the first treatment and (4  1.91)/35 or 16.9% for the
second treatment.
DISCUSSION
This is the first use of the PfMSP1 HTA to study COI in an
area of high malaria transmission. In the present study, Mala-
TABLE 2. Characterization of PfMSP1 sequence variants among









1/004 2 1 IND
1/006 1 REI
1/008 4 1 IND
1/009 10 2 4 LTF
1/010 3 1 2 LTF
1/014 4 1 2 LTF
1/018 ETF
1/021 ETF
1/028 9 1 IND
1/030 4 4 LTF
1/034 6 3 1 LTF
1/041 ETF
1/050 4 1 IND
2/007 3 1 IND
2/008 4 3 LTF
2/011 6 2 3 LTF
2/012 6 REI
2/014 ETF
2/015 7 4 LTF
2/018 1 1 IND
2/019 4 1 3 LTF
2/020 3 1 LTF
2/022 5 2 2 LTF
2/025 1 1 LTF
2/027 2 1 IND
2/033 4 1 1 LTF
2/039 3 1 IND
2/040 ETF
2/041 6 1 IND
2/042 8 5 LTF
2/044 5 1 IND
2/047 3 1 2 LTF





1/008 4 1 IND
1/009 11 1 IND
1/014 4 1 IND
1/030 ETF
2/012 5 1 1 LTF
2/014 5 REI
2/025 ETF
2/044 8 3 2 LTF
2/047 2 1 IND
2/058 2 REI
a Sequence variants in the second or third episode are shown.
b ETF, early treatment failure; LTF, PCR-corrected late treatment failure;
REI, PCR-corrected reinfection; IND, indeterminate (PCR-corrected episode
containing one variant present in 10% of all participants).
TABLE 3. Probability of reinfection in patients whose initial and
recurrent episodes shared a single frequent










1/004 2 0.108 0.204
1/008 4 0.158 0.497
1/028 9 0.14 0.743
1/050 4 0.158 0.497
2/007 3 0.108 0.290
2/018 1 0.108 0.108
2/027 2 0.108 0.204
2/039 3 0.158 0.403
2/041 6 0.14 0.595
2/044 5 0.14 0.530
Second treatment
1/008 4 0.140 0.453
1/009 11 0.108 0.716
1/014 4 0.140 0.453
2/047 2 0.158 0.291
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wian pregnant women carried a mean of 3.82 PfMSP1 sequence
variants. Using colony PCR as the gold standard, we conclude
that the HTAs can accurately measure the relative proportions
of each PfMSP1 variant. Further, independent of parasite bur-
den and primigravidity, the risk of treatment failure increased
23% with every unit increase in COI; this result is consistent
with the findings of Lee et al. (13). To our knowledge, this is
also the first report showing that HIV coinfection is associated
with an elevated COI.
The HTA method has several advantages. First, it is more
sensitive to minority variants than nested PCR and is less
prone to cross-contamination (15). Second, as we demonstrate
here, it is quantitative and capable of measuring variants rep-
resenting as little as 1% of the parasite population in an indi-
vidual host. Third, because it generates highly reproducible Rf
values, one can determine the prevalence of individual variants
in a given population. Fourth, the combination of HTA and
colony PCR allows for the rapid cloning and sequencing of
variants.
The major disadvantage of the HTA is that it requires the
use of radioactive probes. However, once HTA methods are
firmly established, related nonradioactive methods, such as the
heteroduplex migration assay (HMA) can be developed (4,
24); whether the HMA can detect low-abundance variants as
well as the HTA remains unknown. In addition, the HTA is
also potentially limited in its resolution, in that multiple vari-
ants, with similar sequences, could run at the same position on
the gel; these variants could only be detected by cloning and
sequencing. A third disadvantage of the HTA is the possibility
that observed variants are actually recombination artifacts. Be-
cause the probability of recombination increases with the size
of the amplicon, the degree of recombination of a 400-bp
PfMSP1 block-2 amplicon would most likely be less than the
recombination observed by Tanabe et al. (23). However, this
drawback holds for all PCR-based methods.
HTAs, combined with a binomial probabilistic approach,
represent a new way to estimate drug efficacy. Alternative
categorical methods for “PCR correction” suffer from several
problems. First, since non-HTA methods may not be able to
detect minority variants, sharing of such variants by enrollment
and recurrent samples might be missed and failures misclassi-
fied as reinfections. Second, since specific variants may pre-
dominate in certain areas, reinfections, by these common vari-
ants, might be misclassified as failures. In contrast, HTAs can
detect minority variants. Thus, inferring dichotomous out-
comes (failure versus reinfection) for PCR correction methods
can be misleading. However, by calculating the prevalence of
each variant in a population, we can determine the probability
that each individual patient originally scored as indeterminate
failed and, by summation, the estimated overall failure rate.
There are several limitations to this method. First, if a
treated patient were reinfected but bore gametocytes from his
initial infection, then this patient might be misclassified as a
failure (25). This is a problem facing all genotyping correction
methods. A second potential limitation of the binomial
method, which considers the prevalence of the recurrent vari-
ants, is the assumption that the variants are transmitted inde-
pendently (i.e., a single mosquito bite only contains a single
parasite variant). Although this assumption has not been di-
rectly assessed in Malawi, in 2003 in the Republic of Guinea
Bissau Arez et al. (1) found single PfMSP1/MSP2/GLURP
alleles in ca. 50% of the P. falciparum-infected mosquitoes. A
third potential limitation is the choice of bin size. Although it
is possible that different variants may be counted within the
same bin and smaller bin sizes might be preferable, in our
study we observed only one individual out of 125 for whom this
may have happened. A fourth limitation is that this method
does not lend itself to survival analysis, a method commonly
used in drug efficacy studies.
In summary, by HTAs the COI was found to be elevated in
Malawian women with HIV and in those who failed therapy.
Assigning a probability of failure to specific recurrent episodes
mitigates misclassification for clinical trials in Africa and other
high transmission areas. The method, developed here, will now
be used to compare the efficacy of SP, SP plus artesunate, and
SP plus azithromycin within this study population.
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